Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about the anticipated results of Pelage's Phase 2a clinical trial for their topical hair loss treatment, PP405. Users speculate on when the results will be available, noting that delays might indicate less successful outcomes.

The user is taking 0.5mg finasteride and 0.5mg Loniten orally daily, using Eucapil twice weekly, and Minoxidil foam once daily for hair loss. They believe Eucapil effectively stops hair loss despite side effects like breast growth.

A user offers an extra bottle of Koshine 0.5% solution for hair loss. The discussion involves interest in trying Pyrilutamide for hair treatment.

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

The conversation discusses using sunflower oil as a carrier oil with rosemary oil for hair loss treatment, as it doesn't leave the scalp overly oily like hemp seed oil. The user also mentions avoiding minoxidil due to side effects and using rosemary oil to reduce hair fall and promote new growth.

A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.

A user shared their progress using liquid minoxidil for hair regrowth and plans to switch to foam minoxidil due to flaking. They asked if the foam version would maintain their results and mentioned considering adding finasteride and a derma pen soon.

PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.

The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

Hair loss from headspin friction might be improved with minoxidil if follicles are healthy. Finasteride isn't needed, and microneedling is suggested.

The launch of Pyrilutamide as a potential hair loss treatment, with people discussing whether it is better than treatments like finasteride and minoxidil. Some participants have also discussed the risks associated with importing drugs from China.

The user is seeking alternatives to Minoxidil for hair growth, currently using 0.1% topical finasteride and 2% ketoconazole shampoo. Suggestions include microneedling, red light therapy, rosemary oil, and other topical treatments like cetirizine, Stemoxydine, and Latanoprost.

The conversation discusses the potential of new hair loss treatments, with a focus on pyrilutamide, gt20029, and topical alfatradiol, and the possibility of improving their effectiveness through methods like increased concentration and microneedling. Dutasteride is also mentioned as a stronger option.

A user shared their 10-month progress using 1mg finasteride daily and micro-needling, noting significant hair regrowth and no side effects. They plan to add oral minoxidil to boost hair density.

The conversation discusses alternatives to 5AR inhibitors for hair loss treatment, suggesting options like minoxidil, KX-826, pyrilutimide, microneedling, and topical bicalutamide. Concerns about side effects and the effectiveness of these treatments are also highlighted.

A user shared a video suggesting that 0.5mm microneedles are most effective for hair growth. Other users mentioned different microneedle lengths and advised consulting a dermatologist for personalized treatment.

Microneedling with needle lengths of 1.5mm to 2.5mm to stimulate hair follicle stem cells for potential hair growth. Using needles longer than 2.5mm is not recommended due to risk of puncturing veins in the scalp. A dermastamp is suggested over a roller.

Users discuss the release of Pyrilutamide 1% outside China and its potential effectiveness compared to 0.5%. They also mention using Minoxidil, Finasteride, and RU58841 for hair loss treatment.

The conversation discusses past and current hair loss treatments, with the user reflecting on expensive peptide treatments like topical Dutasteride, Latanoprost, and others, which were ultimately deemed less effective than oral Dutasteride and Minoxidil. The user now prefers the latter due to their cost-effectiveness and efficacy.

The conversation discusses hair regrowth using finasteride, minoxidil, ketoconazole shampoo (Nizoral), and microneedling as treatments. Users are sharing their experiences and results with these specific hair loss treatments.

Delayed release oral minoxidil is seen as a promising advancement for hair loss treatment, offering safer, higher doses and more consistent hair follicle stimulation compared to current options. However, it is not expected to replace finasteride or dutasteride, as it does not prevent androgenetic alopecia.

The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.

Finding a topical solution for hair loss, with specific treatments mentioned such as Minoxidil, Finasteride and RU58841.

Nanoxidil is considered to have better absorption and fewer side effects than minoxidil, with added DHT blockers. The user is questioning if switching to the more expensive Spectral.DNC-N is worthwhile compared to cheaper options like Kirkland minoxidil.

Topical bicalutamide is discussed as a potential hair loss treatment. Other treatments mentioned include Minoxidil, finasteride, and RU58841.

Setipiprant and bimatoprost are being discussed as potential future treatments for hair loss. Some individuals have started testing setipiprant before FDA approval, but no progress updates are available yet.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

The user noticed increased hair fullness after using a minoxidil and finasteride oral capsule but is unsure if the 1.25 mg minoxidil dose is sufficient. They are considering switching to a higher dose and are waiting for a dermatologist's advice.

The conversation discusses the use of castor oil and pumpkin seed oil for hair thickness and shine, with concerns about oral consumption. The user is already using Minoxidil, finasteride, and RU58841.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.